Hyperlipidaemla Education & Atherosclerosis Research Trust UK (A company Ilmfted by gu•rnnts•) Reglstered numbor: 02631049 Charlty number: 1003904 Trustee8' report and flnanclal statements for the year ended 28 February 2022 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Contents Page Reference and admlnistratlve dètails of the charlty, Its trustees and advlsers Trustees. report 2-18 Indepondent audltors, report 19. 22 Consolldated statement of flnanclal actlvltles 23 Consolldated balance sheet 24 Charlty balanca 8heoi 26 Consolldated statement of cash flows 28 Note8 to the flnanclal statements 27-41 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Refvrenco and administrative dgts11$ of tho charlty. It8 tru8tMB and adv180rn for th• year ended 28 February 2022 Trust•os Dr P H Gr8en, Chairman Mr S D Boley ACA, Trustea Professor E A Hughes. Tru8tee Ms G Howells, Trustee (resigned 24 March 2021) DT D Neety. Trustee Dr A Ree$. Trustee Ms J Bennett, Trustee Dr R Cramb, Trustee Ire8ign8d 8 June 20211 Ms T Kènnerley, Truste8 Mr B A Dobson, Trusie8 Mr A J GTe8v8$, Trustee Dr D B N Dalta. Trustee Mr T M Dixon, TruBlee Mr N R Phipps, TNstee M8 A Tyler. Trustee Mr S Handrean. Trustee Ms N S Kim. Trustse Comp•ny r•gl•t•rod numb•r 02631049 Charlty roglstered number 1003904 R•gi•t?red offlc• 7 North Road, Maidenhead, Berkshire, SL6 1PE Cornpany ••crnt¥ry & Chl•f ex•cutiv• officer Ms J Payne Independont audltorn Moore Kingston Smith LLP, 6th Floor, 9 Appold Street, London EC2A W OUY Ihpact Ib 2021-2022 HEART UK rwcAoLE5T￿LCml￿T￿ rublic hwarcbCSS (Iba Suppoyt Hcaltkc(4fC fYofcssiob(415 3,301 HCPS subscrfbed to our &ne¥ A3816intrEo5eon the￿O￿$Y 1.156 people a￿Sed our cholesrerol helpllne rated the helpline as 'excellenf or'good, 507 www HCPS attended our onlSne Cmnlcal Conference 56.210 1.65 people sub5cdbed to our e.news peoplè accessed the HEART UKweblCe 2.513 HCPS vlewed our educatlonol weblnars Artlncreu5eot31011 ￿theye¥b￿Sye 81,11 prlnted ma¢erfalsweredlsrrlbuted to pattentswlth Wi chc4e5twd. re50urce5 dlstrfbuted to chlldren and young people of HCPswho attendèd ourweblnars reported being'mord or'much more, ctsnffldent treating their patlents for hlgh cholesrerol because of atteThllng Tacklih9 C4ol¢st¢rol 1,800 10.051 HCPS edutatèd Ihrough our new established Prlmary Care Education Pro8ramrne- Tacklin8 Cholesterol Together wlth the NHSIMCIAHSN Dlgkal materlals were downloaded People￿eWed ourvldeo resources 161.800 Impressions on Twitter- oursodal medla platfomi targeted at HCPS 11.005 ofyou viewed our Facebook posts of you vie￿ed our Instagram posrs Headline Impact Figures for 202112022 Registerèd Charity Number 1003904 Annual report incorporating a Directors, Report and Accounts for the year ended 28 February 2022 OBJECTS AND ACTIVITIES Introductlon HEART UK is the UK'S onty charity focussed on cholesterol and lipids, 1Spids belng a medical term meanins 'blood fat, and whilst there are numerous blood fats, cholesterol 15 the most common. For this reason we will refer in thi5 report to just cholesterol, but assume this means all blood fats. In 2002 two charities merged to form HEART UK. The British Hyperlipldaemia Associatk)n, a health care professlonal focused organisation and the Family Heart Association, a patient focused organisation. HEART Is an acronym and stand5 for Hyperlidaemia Education and Athersclerosis Research Trust. As a result of thi5 merger, HEART UK seThes patients, their families and health care professlonals, in additlon to the general public who may not be aware they have a cholesterol Issue. Almost half of UK adults have raised cholesterol, puttlng them al an increased risk of heart attacks, strokes and vascular dementia. Raised cholesterol Is the most common modrfiable risk factor for cardSovaKular dlsease and it can affect anyone, even the youn8 and otherwise healthv. C•rdlovascular dlsease ICVDI causes almost one-thlrd of all deaths In the UK - on average, one person dles every three mlnutes from CVD. More than 7 mlllion people are livlnB wlth CVD in the UK. Even chlldren can be at risk around I In 250 people have the ienetlc condltlon famlllal hypercholesterolaemla IFHI, whSch lead$ to hl8h clK+lesteml and an Increased rlsk of heart dlsease at a young age and even heart attacks in chlldhood. Currently, less than IO% of those wSth FH have been diagnosed. Millions of people with raised cholesterol caused by other factors are slmllarly unaware of the risk they face. HEART UK is o registered charity and a company limlted by guarantee. We also have a trading subsidiary, HEART UK TradinB Company Limited through which the majorlty of our corporate sponsorship activity 15 conducted. The charlty's objects as set our In our constitution are.. 'To relleve those Suffering the effects of heart disease and in particular lipid disorders, familial hyperlipidaemias and related conditions, to promote the relief of slckness and the preservation and protectlon of health by reducing the incidence of vascular disease in the general population of the Unlted Kingdom, to provi(le counselling and advice to relatives of those dia8nosed with inherlted heart disease and to promote the study of cause5, diagnosis and treatment of lipSd disorders and associated metabolic disea5es.' Aims and objectlves HEART UK provides specialist advice and expertise to indivlduals, families and health care professionals working to improve the services available to those who live wrth high cholesterol. Our slnBle focus means we have been able to build a highly influential and collaborative model, bringing specific patient experience and 5cientiflc Snformation together to create effertive patient communications and influence Government policy. Our focus is enlirely on helplng people know and understand their cholesterol levels and take appropriate action. We believe that investing our limlted resources on thls one intervention is the most impactful way of tackling premalure cardiov05cular disease, disabilitles, illness and avoidable early deaths. We aim to prevent people getting heart disease and dying from avoitlable heart attacks, strokes and other conditlons that high cholesterol can cause. Volunteers Volunteers fomi a vital part of HEART UK'5 actlvltles. We continue to beneflt from a range of volunteers including health care professlonals serying on our committees who wlllingly glve up their tlme to help us be the lead voice on cholesterol and shape the way cholesterol is dlagnosed and managed around the UK. We are olso very lucky to be supported by our Amba55adors who are the HEART UK voice in their communlty,, they help ralse awareness of the dan8er5 of cholesterol. We also benefit from a lot of 5UPPOrt from dedlcated fundralsers helplng to raise funds for our essentlal work. The Trustees wlsh to extend thelr sincere thanks to all the volunteers who support HEART UK. Our single focus mean5 we have built a hl8hly Influentlal and collaboratlve model, brln8in8 speclflc patlent experience and sclentific infomiation tO8etherto create effective patlent communlcations and improvin8 public polity. Publlc Benellt In reporting on the objectives and achievements of the charlty, the Trustees have glven due regard to the Charity Commission guldance on public benefit under the Charities Act 2011. HEART UK constitutes a public benefit entlty as defined by FRSIO2. Dlverslt uali nd Incluslon We have a Diverslty pollcy that was last updated in April 2020 and is reviewed every three year5. We are committed lo ensuring that the values of equality. diversty and respect are embedded into everything we tr). Anyone within the UK can access our 59rv5ces. Tho Charity Governanc• Cod• We aim to abide b the Charit Governance Code. ACHIEVEMENTS AND PERFORMANCE Background Informatlon We work closely with lipidologists, scientists, doctors, nurses, pharmacists, dietitian5 and other health care professlonals across the NHS, plus food companies, medicine manufacturers and across government bodie5 such as NHS England and the Office for Health Improvement and Disparity to ensure patients are provided with the information and sUPPOrt they need to manage cholesterol arTrd live a lon8er, heatthier Ilfe. Our focus is mainly on savlng lives vla raislng awareness, service delivery and educatin8 healthcare professionals and the public and patients. However, we work to advocate on behalf ol people with hlBh and Inherited cholesterol condltions, effectinB crucial chan8e in policy and standards. Our recent engagement with key opinlon leaders resulted in successes over recent years; Contrlbutin8 towards consultations on clinical guidance, from diagnosi5 through to treatment, long term management and the role of new medications Provldin8 evidence & updating NICE guldellnes and di55eminatin8 these to healthcare professlonals and advislng on guidance documents for healthcare commissioners Publishing our Statements of Care: settin8 out best practlce for treatin8 Patients are used around the UK and world and improve patient outcomes Our FH Days of Action resulted in political prioritisation of FH Our National Cholesterol Month ra15e5 awareness of the dangers of cholesterol to millions of people Award wlnnlng awareness and Influencing campaign5 Cholesterol to be a prlorlty within the health servlce Changed the Armed Forces policy from FH labelling people as unflt to seNe, to allowing those to enter the Armed Forces and serve thelr country. Workln8 towards a national lifelong reglstry for FH Identifying people at a much younger age. in the case of FH in childhood Over the next five year5 we will contlnue to build on these successes, ensurlng that the NHS dellvers its tar8ets published in thelr NHS Long Term Plan and continues to prloritise and adequately fund cholesterol related diagnoses and support services. The team DurSng 2021122 the COVID-19 pandemic. The HEART UK team als0 continued to work hard in order to dellver our objectives and support our beneficiaries. Providin9 scientificully bt7sed, factuolly occurote Informotion We provlde a range of information both on and offline covering each of the conditions we support. All our information is scientifically based and factually accurate. For people who have been Identified as at risk of or having FH, information is scarce with GPS potentially unfamiliar with the condltion and referra15 to Specialist lipidology Consu￿antS which can invofve very long waitin8 times. This can be a very anxious time, whlch Is not helped by a plethora of confusing and contradictory informatlon available online. HÉART UK addresses thi5 issue by working wlth GP SurBeries and clinic5 acros5 the country to offer patients user-friendly, evidence-based and practical information and advice on how to understand and tackle high cholesterol. All our Information and advice 15 produced by our specialist cardiac nurses and dieticians and is supported by our Medlcal, Scientific and Research Commlttee. This information and advice is regularly updated. The m05t popular leaflets include 'UnderstandlnB Cholesterol, and 'Healthy Eatin8', but we also provide information specifically for certain groups, such as children with FH. We have booklets aimed at children of different ages Ilving with FH18enetically hlgh cholesterol) to help them understand their condition. We aim to ensure that potlents who have been dlagnosed with hi8h cholesterol have access to quality information to explaln and advlse them. We monltor the uptake and re-orders of Ilterature by GP practices as a proxy indlcator for this access. We provlde literature to over 1,200 GP practices wlth these praLtILe5 Luiiliiiuiii¥ lu yldLe reorders (or our literature which we supply free of charge. We know that OLbr literature provision does increase access to qualr¢y infomiation. Callers to our Cholesterol Helpline frequently report they received our literature via their GP and are getting in touch as they have further questions- demonstratln8 both that the need for information exists and that HEART UK'S services are helping to address this need. .1 hove used these bookletsfor mony years n(￿. They ore ideollor our potlent. Very Potlentfrlendly and I hove hod greotfredback about them. Thonk you., Nurse. Worwick The HEAR T UK Cholesteml Helpllne Our dedlcated Cholesterol Helpline offers information and support over the phone or by email. The helpline responds to a clear need for advlce in dealing with newly diagnosed raised cholesterol or concerns about famlly history of heart disease. Obtaining GP appolntments, limfted tlme and information available from GPS, waitin8 Ilsts for lipid specia115t5 and a profusion of misinformation on the internet all contribute to a situation where people lack accurate information or tailored advice. People who Bre worried about raised cholesterol, or not sure what to do about their cholesterol levels often have nowhere to turn for advice and end up doing nothing- or worse; relying on inaccurate advice and information from the internet which can endanger thelr health. The HEART UK Cholesterol Helpline is uniquely run by expert cardiac nurses and specialist dietitians, supporting anyone that contacts us to help them manage their cholesterol. In 2021122, over 1,400 people accessed our helpllne for support, including people newly diaBnosed with high cholesterol seeking help to understand their condltlon and the artions they need to take to ameliorate it. The Helpline also supports people diagnosed with, or who have lost a family member to, the inherited high cholesterol condition, FH. These enquirie5 can be complex and require expert knowledge and professional handling and are often 'time heavty. The Helpline team of speclalists provide the information and advice in our literature, on our website, in our social medla posts and take part in conferences and webinars, radio broadcasts and other PR activities designed to raise awareness of the dan8ers of high cholesterol and the steps individuals can take to manaBe it. Our Helpline users tell us how important our servlce is to them and often support our advocacy and fundraisin8. "I t7m seelng my GP next week ond wanted to check out my lipid profile wlth you ond the best medlcatlon 9olngforword to lower my LDL l om struggling with my current medicotion. Thunk you. I nowfeel In control ond reody to speak to my GP. ° Helpllne user. Healthcore professlono15upport Support for healthcare profe551onals over 2021122 We provlded over 88,￿0 pieces of literature to heatthcare profes51onals free of char8e. 99.2% of those rated the literature found it invaluable or very helpful. 97.8% of people said they glve the Ilterature to patients durlng their consultations. We partnered with the NHS, the Academic Health Science Network and the Accelerated Acce5S Cc+llaboratlve and developed our Primary Care Educatlon Pro8ramme through a Tacklin8 Cholesterol Together, campaign: We have provided webinars to over 2,000 heakhcare professionals, èround half of which were from primary eare with 95.6% of people saying our webinars impacted their knowledge of the topic. Developed learning e-module5 around statln Intolerance, identifyin8 FH in Primary Care and Lipid Management Pathway. Although these were wrttten for primary care, healthcare professionals from across ihe system have accessed them. 91.3% of the people sald these e- modules Improved their confidence with the topic. There were also clinlcs and videos included. FH Intelligence Network We provide a source of network support through our regular monthly telephone conference ca115 to bring together health care professionals dealing with FH. They discuss challenges, share information, best practice and learn from each other. Lipld Interest Group Thls is a group of over 120 allied health professionals, from FH and apheresis nurses to GP practice nurses, who meet once a year to network and share information. Once a month they circulate a 'round robin, featuring a recent examplè of their wort(. This proves useful to all. Annuolscientific confvrence With the COVID pandemlc contlnuing, we held our flagship Annual Scientlfic Conference in July 2021 virtually with over 5CII attendees. 100% of the attendees said they would be able to apply the learnings in their day to day practice to improve patient outcornes. We plan to be back with a hybrid offering. Although we are encouraging everyone to 8et together face to face, we do understand some people may need to join virtually. Nutrition Acodemy Our Nutrition Academy 55 an online platform aimed at provlding information and training to all health care professionals who deliver dietary advice to individuals dia8nosed with hlgh cholesterol. We have recognised the lack of dietetic support in speciallst areas. and the challenges in accessln8 these seryices in other area5. Thls has led to non-dietetically traine(i staff feellng responsible for advising patients. The purpose is to provide an online centre of excellence to ensure health Ca￿ professionals can provlde accurate, evidence-based information to their patients about how to manage their condition to reduce their risk of cardiovascular disease. An advisory panel of experts in the field of nutrition and dletetics helps us steer the pro8ramme; we are currently in the process of reviewing funding opportunitles to expand its remit to include an online e-learnln8 platform. The impart at a personal level- Gurcharan's slory Gurcharan. 44, married wSth a 9-year-old daughter, had a busy Job as an a551Stant store manager of a large supermarket. He had an active lifestyle- walking to work every dayi running once a weeK eating a good diet. didn't smoke and was not overweight. Gurcharan had been experiencing chest pain but it wa5 Put it down to stress and anxlety. His dortor organiied a routine scan. Six weeks later and four days before the Covid-19 lockdown in the UK, Gurcharan 8Ot a call from his cardlologist as hls Scan result5 had come through. "I hod o blockuge In my left ortery, ond I wos asked to make an urgent app￿ntment to see him the next d¢ry. I neorfyfolnted with the 5hocV, says Gurcharan. He contlnue5,"New5 ofsome coses of Covid hadlust storted. 6nd oll the h05pltalstoff were oll weoring PPE which wa5frightenlng ond added to my anxiety. I wos worried becouse both my porents hod heart byposs opemtionsfvr blocked orterles in thelrS0's, ond my uncle was just 49 ond hod the same operation, I was immediotely prescrlbedstotlns ond onotherfvllow up appointment wos mode." NatUTally. Gurcharan wa5 worried, confused and had many unanswered questions about hls condltlon and hereditary CVD whlch he couldn't find the answers to. Luckily, doing a Google search, he found HEART VK- The Cholesterol Charlty's webslte which realty helped him to understand thlngs. "I rong the HEARTUK Helpune ondspoke to thelrspe¢loltst cardlac nurse who was so helpfvlond klndandqove me lots 01￿lUable infvrmotlon. support ondconfldence. Dlscoverlftq HEARfuKwoslustbrflllunt andlh75 been o Ilftlinefvr me. It gove me onswers to oll mv questlon<, concludes Gurcharan. In late June, durlng the lockdown, Gurcharin started to get bad palpitations and his cardiologist brou8ht hls revlew appolntment forward. I wa5 50 scared - ha¥ln8 a heart condltlon and w￿h Covid ever present- made It ten time5 worse. "During the onglogrom. I wos told I h¢7d 17 blg blockt7ge In my left ortery. 15 mlnutes loter, they hodput 0Stent In via my wrlst. Afterwords. In recovery. my cordiologist told me that I was a very lucky guy, that I hod 0 99% bl¢xkoge ond I hod been hanging on Ilke o p￿te of string. I could not thank him enough. At my lust review, I was given all clearAor Inherlted FH ond my cholesterol level Is now low. I still ht7ve no explanotionfor mypremoture heort diseose but wos told that I could still hove o heort ottock in 10 yeurs, time. I've now gone bock to work on o phased return. This eXPer￿nCe has made me rethink my life ond I know thot I need to spend quality time with my wift ond daughterbecause who knows what thefuture wlll bring,: Nntp.. There are Inherfted lipid disorders otherthan genetically proven familial hypercholesterolaemla. which can cause premature cardlova5cular dlsease. Our understanding of these condltlons contlnues to grow and HEART UK is pleased to support people1Svlng wlth these conditions and furtherln8 research. The continuing impact on HEART UK of coront7virus- COV1￿19 HEART UK'S fundraising, as with other charities, was impacted by coronavirus in the lock downs, with events being cancelled. However, during 2021122 we were able to focus on 8etting some of these back up and runnin& although participation was lower than pre-pandemic. We continued to WO￿ to improve the level and qualty Df information available to individua15 about cholesterol, CVD and the impact of COVID-19 on services they receive. During 2021122 we have seen accessing seFvices happen in dlfferent ways whereby elettronit appointments were used and moving into 2022123 we are seeing hybrid models being used. As result, we have learnt improved ways of working. However. there are some frustration5 fett by patients not being able to always see their GP but Instead having an e-consultation. Our own team have embraced hybrid working practlces and as a result we have reduced our office space. COVID has also made people ihink differently about life. Our ways of working have chan8ed to be far more flexible. However, there is a challenge with recruitment. Thls ha5 been well featured in the news and it seems all or8anisations are struggling to recruit and we are no different. M4lor Achlevements During 2020121, HEART UK has had much to celebrate with our campaigning. Thls ha5 been as part ol a programme of activities and buildln8 on last year's success, ensurin8 that cholesterol and familial hypercholesterolaemia IFHI We￿ a priority for the NHS and holdlnB the Government and the NHS to èccount to deliver the targets set in the NHS England Long Term Plan. We publlshed a thought leadership piece in the Health Service Journal statin8 the NH5 is sleep walkin8 into a CVD catastrophe, this set out how CVD was largely disregarded throu8h the pandemlc and how this will mean a loomln8 avalanche of strokes and heart attacks over month5 and years to come. We have been makin8 significant efforts over the last 4 years to 8et FH identrfied as early as possible. HEART UK is the only charity championln8 this since it was proven to be so successful in a research study of 10.095 children and published in 2016. We believe screening children for FH should be national screening programme. Testing children early will lead to whole family screening. There is now a two year pilot underway in 7 areas of England with plans to test 30,1￿0 children. We have made fvrther Inroads for one place for a lifelong reBister for FH. This will help the health Systems across the UK to identify FH in other family members in a systematic way which is both life and cost-saving and in 2021122 we had commitment from the Chief Executive of the NHS to invest in a new system. We have fe(1 into a procurement process and in early 2022 NHS En8land met with HEART UK'S FH Registry Advi50ry Group and put forward a proposal for the re8lStry which was accepted as the best solution. We now await a final decislon and Implementatlon. io HEART UK contributes to many health consultations carried out by various agenctes, including NICE and other similar offices across all countries of the UK. One such consultation was about the NHS Health Checks. We have been championing for this to be reduced from a start age of 40 years old to 30 years old in hi8h cardiovascular risk areas. We also want it more accessible for people to get a cholesterol test and identify other health issues in places outside of the GP practice, particularly in community pharmatists who play a vital role in the population's health. The result of this Consu￿ation is that our recommendations were accepted and we await to hear whether these will be adopted and if so, when. We have kept the pressure on the system to prlorltise cholesterol testing and reportlng and we are pleased to say that we have had success in this area too. A new audit in GP prartices called CVDPrevent launched and publlshed their first set of dats In December 2021. There was little information around cholesterol and FH. However, work is belng carried out to address this and improve the quality of the data. We anticipate better quality informatlon belng published for the second cut of data and publlshed around the summer of 2022. Awareness ralsln8 Responding to the medio Throughout the year we featured in 118 pre55 artlcles. Cholesterol e-News Subscription lo our popular e-news has grown to over $6,0(xi subscrlbers. The newsletter Includes features on healthier eating* bein8 more active and promotin8 fundra15ing activities. According to our service provider, Mailchimpi the open rate is 15% higher than other similar newsletters. Notionol Cholesterol Month We carrled out an awareness raisin8 campalgn to ensure the public were aware of the dan8ers of cholesterol. The aim wa5 to empower people to know and understand their cholesterol numbers and take approprlate èctlon. Leudershlp HEART UK devebped and led a network of heèrt and clrculatory dlsease charltles, Includin8 Stroke Association, Cardiomyopathy UK, Arrhythmia Alliance and Blood p￿ssUre UK. The purpose of the network is to co-operate on mutually beneficial initiativesi particularly campal8n and policv focu5sed. We held a Heart and Circulatory Disease Summit that was hugely successful and as a result we launched our consensus statement whlch is used with key stakeholder engagements to add to the discussion to lead to policy change and CVD remainin8 è key prloritv. PRINCIPLE FUNDING HEART UK'5 approach to fundralsin8 is largely relationship led, through: Individual givlng Sports and challenges li Legacies Corporate partnerships, including food, gyms, clothes recycling, dia8nostics and pharmaceutical companies HEART UK has a commercial participator relationship with our food partner5 whereby a company wlll apply to Use our product approval1080 on their products. These applications are assessed by our expert Product Approval Task and Finlsh Group against a stringent process and a very strirt crlteria. We also have commercial participator relatlonships with companles we have entered in partnership with. HEART UK do not carry out street collections or house-to-house fundraisin81 Other than bag drops for one of the clothes collection seNices. HEART UK uses third party companie5 to assist us with our fundraisin& includin8 our clothe5 collertion services: sports and challenge5; payroll 8iving and legacy. HEART UK has g Safeguardlng and child/vulnerable adults protection policy. This was updated In April 2021 and is reviewed every two years. The Board of Trustees have all our policles in a Trustee manual and are Informed when there Is an update and required to familiarlse themselves wlth each policy. The staff are required to famillarlse themselves with all our pollcle5 each year and are provlded wlth re8ular training. HEART UK Is re8iStered with the Fundralslng Regulator. HEART UK complres with the Charlties Act In re8ard to fundra15in8 and In additlon puts the privacy of our supporter data at the heart of everything we do. We manage personal data respertfully and responsibly in accordance with our published prbvacy policy. HEART UK Teteived an estlmated 10 complaints associated wlth hjndralslng, all of whkh were relatlng to the clothes recycllng scheme and mostly were around the bags not being collected, in thls flnancial year. This is a very low fSgure for the sector. Nevertheless, we are committed to studylng any expression of dissatisfaction and identifying ways to improve. Our fundraisin8 team investigate each complaint, and we do all we can to resolve the matter and ensure supporters are happy with our work. Our complaint procedure Is publicly available on our webslte. Without the fundraisin8 SUPPOrt we would not be able to operate. and we are incredibly grateful for every penny that 15 donated helping us to tnJly save lives and keep families tO8ether. RISK MANAGEMENT The Trustees have assessed the rnajor risks to which HEART UK is exposed and are satlsfied that 5YStems a￿ established to mitl8ate the charity's exposure to those risks. These risks are detailed on a T15k register, reviewed quarterly by our Flnance and Risk Committee and annually by our Board of Trustees. The biggest risks currently featuring on our register are: Cyber fraud. Many charities are experiencing cyber fraud and this has signrficantly Increased during the pandemlc. We consider we have robust procedures in place to best avoid this and have developed a specific cyber fraud policy. Fundin8. We a￿ regularly reviewing the funding Sltuation by continuin8 to have monthlv Finance and Risk Committee meetings. 12 Reliance on individuals. We are focusing on retainin8 Staff as well as recruitln8 good peoplè to the team. FINANCIAL REVIEW Income for the year ended 28 February 2022 totalled £902,9291£754,465 in 20201211 Expenditure on raising funds was £462,3001£304.045 In 20201211 and charltable attivity spendlng was £554,3921£562,278 in 20201211. Of particular note- We received one large legacy durin8 the 2019/20 year totalling £165.SYJ9.09, with a further amount of £76,935.97 in 2021122. We feel very gratefvl to Ruby Ada Watts for thlnking about HEART UK in her will and consldering the tremendous 5UPPOrt we can provide to our beneficlaries with such a huge contribution to our essentlal work. The tlothes collections signSficantly increased, in particular through our partnership wlth icollectclothes. INvESTMEr￿ POLICY Under the Memorandum and Artlcle5 of A5SOCiation, the charlty has the power to invest in any wav the Trustee5 seè fit, The policy of the charity is to adopt a low-risk 5trate8y at present. We have one Investment whlch is low rlsk with no Investment In tobacco, alcohol or arms. RESERVES POUCY The reserve5 pollcy15 Set by the Board of Trustees and reviewed annually. We aim to hold free reserves in the range of 6- 9 months, worth of operating expenditure. Our free reserves at the year end totalled £447,176 which represents just under 6 months. In the Ilght of the effect5 of COVID-19 highlighted elsewhere, our free reserves will fall below our operatln8 8uidelines during the next 12 months. The Board of Trustee5 are fully aware of this and thSs positlon will continue to be monitored by the Flnance and Risk Committee and the Board throughout this perlod. PLANS FOR THE FUTURE Our vlsion Is to.. Prevent early disease and deaths from cholesterol and other blood fat Ilipldl condltions in the UK. We aim: To increase the number of people bdentified in the UK with inherited lipld condltions from 25,000 to 50,000 by 2025. For people to know and understand their cholesterol and other blood fat Ilipidl levels and take appropriate action. We intend on achieving this by: 13 Influenclng health and political systems to ensure a focus on cardiovascular disease prevention with an implementation plan to identify and treat people with high cholesterol Influente lipid data to be captured and reported Educate health Ca￿ professionals & the public about inherf(ed and preventable lipid conditions and actions they can take Raise awareness ol inherited and non inherited lipid conditions thereby empowerin8 people to take action Support those diagnosed & their families and sUPPOrt those diagnosed to take appropriate action Raise funds to enable us to deliver our artivities During 2022123 we wlll: Continue with our Cholesterol Helpline en5urlng we provide the best ways for people to get in touch with us Regularly review our Information provided to ensure it Is up to date Continue to build our communicatknn channe15 to further Increase our reach and Influence, particularly dlgltal and online Publish approprSate expert papers in order to ensure best practice treatment and mana8ement of lipid patients Continue to educate the publici patients, famllles and healthcare professionals treating patients with lipids ContinLbe to ensure CVO Is a key priority for the Government Continue to lobby for FH to be identified as early as possible; In children and adults Continue to lobby for data to be captured and publlshed by NHS England and the Office for Health Improvement and Disparity so we know exactty what the pictu￿ looks like with lipid patients both locally and natlonally, this will include improved cholesterol and FH reporting throuBh CVDPrevent and a natlonal Ilfelong FH registry. STRUCTURE, GOVERNANCE AND MANAGEMENT The chartty IS 8overned by a Board of Trustees who are legal members and also directors of the charity for the purposes of the Companies Act. The Board seis the strategic direction of the charity ènsuring that the charitable purposes are met. The Board of Trustees delegète the day to day running of the charity to the Chief Executive. HEART UK conslders each of the Trustees to be independent in character and jud8eTnent: and understands that they have no relationship5 that are likely to affect, or could appear to affect, their judgements with regard to HEART UK. Declarations of interest are required from new Trustees upon appointment, annually and every meeting of the Board requires that any new interests are declared. No remuneration Is provided except for reasonable travel and subsistence costs. These costs totalled £0 during 20211221£0 in 20201211. During 2021122 we had change5 to the board of trustees with Gaenor Howells and Dr Robert Cramb stepping down. There are a number of committee5 and task and finish groups that serve the Board of Trustees to a5SlSt in the delivery of our objectives: 14 Committees Flnance ond Risk Key areas for this committee are- To be respon51ble for financial and general business affair5 of the charity including: Risk Management - Financial Control Mana8ement Audit and presenting final accounts to the AGM following Board approval. Reviewin8 annual account5 prior to Board and then AGM approval. Communicotion5 ond Fundmising Key areas for this commlttee are: To oversee our communications and channels used To oversee our fundraisin8 activitles The Medicol and Sclentific Research Committee IMS&RJ Oversees the Annual Conference, the development of research and 5peclallty tralnin8 pro8rammes, clinical 8uidelines development and creating and updating our information. The Healthcore Committee Key areas of interest.. Provldes up-to-date Infomiation to health care professionals who care for patlents and thelr famllies wlth lipid disorder5. They co-organi5e the Health Care and Patient part of the Annual Conference. Compoigning Advises on publlc affairs and pollcy activitles to hl8hli8ht the importance of cholesterol and CVD. Task and finish rou These 8roups meet when there is a task to be actloned: lipoprotein Aphertsis Key areas of interest: To promulgate guidance for the clinical indicatlon for lipoproteln apheresis. To review and recommend the criteria of efficacy of performance in the UK IAsse5sment to be based on Registry data Sointly formed by HEART UK and the Royal College of Physicians), To educate society In general about Apheresis as a treatment. FH Registry Advisory Group 15 Thls group oversees the Governance of the FH Registry. Conference or9onising This group organi5es the annual sclentific conference usually held in JunelJuly over a 3 day period. GrontAwords This group oversee our grant scheme and review applications, although this is currently on hold. Educotion This group oversee our educatlon programmes. Policy Development Operates to develop, oversee and revlew the policies of the orBanlsatlon. ProductApproval For approved commercial products that bear the HEART UK1080. The group operates withln an ethical and 5cientiflc policy framework to evaluate produrts for approval. CVD Colloboratlve This 8roup meet to drive forward partlcular campaigns around changln8 health policy for the NHS and Government. UK Natlonolscreening Committee Thls group drives forward our campaign for the introduction of chlld-parent screening for FH. The Simon Broome Steering Committèe (secretoriotj Is responsible for directing research based on a national cohort of over 3.500 patients wf(h famlllal hypercholesterolaemia land severe hypertflBlyceridaemial. STAFF A mana8ement team, consisting of the Chief Executfve, Senior Fundralsin8 Manager and the SeThices Development Manager allows for distribution of or8anlsational responsibility. The Chief Executive has particular responsibility for issues relatlng to governance and forthe financlal mana8ement of the or8anisation. HEART UK has 5 permanent members of Staff, 2 full time and 3 part time14 full time equivalentl. The Trustees would like to record their appreciatlon of efforts of the staff, who have a8aln made an enourmous tontribljtion to the succes5 Of HEART UK durin8 the year. PAY AND REMUNERATION The Finance and Risk Committee review the salaries of the staff and advise the Board on any recommended changes. This 15 dictated by market forces and affordabilitv. 16 The remuneration of the Chief Executive is assessed by the Board of Tnjstees. This includes conducting a 360 degree assessment; internalty and externally, market forces* performance and affordabillty. AUDITOR The audltors of the charity and tradlng company are reviewed by our Board of Trustees and appointed as appropriate at our Annual General Meeting. TRUSTEE APPOINTMENT, INDUCTION AND TRAINING Trustees are appointed in accordan￿ with HEART UK'S constitution, taking into account the benefltS of appolntlng a person who is able, by virtue of their personal or professional qualrfications, to make a contrlbution to the pursuit of the objects or the management of the charity. Trustees consider the skills gap on the Board of Trustees. Trustee vacancles are openly advert15ed an(1 recrulted followlng an interwiew and selertion process and then proposed and appointed at the AGM. HEART UK undertakes an Inductlon programme for all new trustees, Including inductlon materlals relatin8 to Its purpose and finances, the powers of trutees and information about the day to day running of the organisation. Key documents are provided, such as the constitution. account5, minutes of retent meetlngs and policie5. Trustee5 continue to be supported through onBoin8 training. SMALL COMPANIES REGIME This report has been prepared in accordance wlth the special provision5 relating to small companles within Part 15 of the Companies Act 2006 CONSIDERATION OF GOING CONCERN The company continues to adopt the 80ing concern basls in preparing its financial statements, The trustees have assessed whether the use of the going concern basis Is appropriate and have conSide￿d possible events or conditions that might cast slgnlflcant doubt on the ability of the company to continue as a going contern. The trustees have made this assessment for a perlod of at least one year from the date of approval of the financial statements. In particular the tnjstees have considered the company's forecasts and Pfojections and have taken account of the Coronavirus pandemic. A5 part of the going concern review the trustees prepared a detailed, forward-looking cash flow scenario, based on the most reallstic assumptions available at the time. In thls scenario the company had adequate re59urces to continue in operation for at least tWe￿e months from the approval of the financlal ststements. STATEMENT OFTRUSTEES, RESPONSI8IUmES The Trustee5 (who a￿ also directors of company for the purpose of company lawl are responsible for preparing the trustees, report and the financial statements in accordance with applicable law and Unr(ed Kingdom Accountin8 Standards (United Kingdom Generally Accepted Accounting Practice). 17 Company law ￿quireS the Trustees to prepare financial statement5 for each financial year which give a true and fair view of the state of affairs of the charitable company an(1 the group and of the incoming resources, including the income and expen(iiture of the charitable 8roup for that period. In preparing these financial statement5, the Trustees are requlred to.. select surcable accounting policies and then apply them conslStentlv4 make judgments and estimates that are reasonable and prudent; state whether applicable UK Accountin8 Standards have been followed, subject to any material departures disclosed and explained in the financial statements: prepare the financial statements on the going concem basls unless It is inappropriate to presume that the charlty will continue in bu5iness- and observe the methods and princlples in the Charitie5 SORP. The Trustees are responsible for keeping proper accounting records that dlsclose wlth reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statement5 comply with the Companies Act 2006. They are a150 responsible for safeguardlng the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. AUDIT INFORMATION So far as each of the Trustees at the time the Tru5tees' report Is approved is aware.. there is no relevant Informatlon of which the auditors are unaware. and they have taken all relevont steps they ought to have taken to make themsefves aware of anv levant audit informatlon and to establish that the audltors are aware of that Informatlon. AUDITORS A resolution for the appolntment of auditors will be put to the forthcomlng AGM. THANKS FROM THE CHAIR OF TRusfEES I would like to extend my personal and sincere thanks to our de(Ilcated and high￿ commltted and capable staff at HEART UK, to my Board of Trustees, our Commrttee members, Ambassadors and volunteers who continue to give their valuable time, commitment and amazing contributions to help HEART UK truly deliver a world cla55 service for our beneficiaries. Authorlsed by the Trustees on. ZI. and slined on their behalf by: Dr Peter Green. Chalr 18 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Independent Auditor8, Report to the trustees of HEART UK Opinion We have audited the financial statements of Hyperfipidaemia Educslion & AtheTosclero$is Research Trust UK {Ihe 'company'l for the year ended 28 February 2022 which comprise the consol￿ated Statement of Financial Activities, the Group and Parent Charitsble Company Balance Sheets, the Con¥olidated St8t&menl of Cash Flows an(J notes to the financial 8tslemenls, including a summary of signlfl¢anl a¢¢ounting policies. The financial reporting framewo￿ that ha5 been applied in their preparation 1$ appluble law and Unitèd ￿'ngdoM Accounting Stsndards {Uniled Kingdom Generally Accepted kcountsng Pr&ticel including FRS 102 "The Financial Rfjporting Standard Applbcable in the UK and Ireland" In our opinion the financial statements.. gNe a true and fair view of the stat8 of the group'8 and the parent Charitab￿ company's 8ff8irs as al 28 Fabru8ry 2022 and of the group's incoming resources and applicalKin of resources, including its income and expenditure. for the vear then ended., havè been properly pr8pared in accordance Unitsd ￿'ngdoM Genèrally Accepted AccounliThJ Pra¢ti¢•', have been prepared in accordance with the requirements of the Companies Act 20(fj and tho Chafille8 Acl Basle for oplnlon We conducted our 8udil in accordance with Inl6rnatsonal Stsndard8 on Audlling {UK} I ISA¥ IUKI") and applicab law. Our re8ponsibililies undar th08e 8tandard8 are further de8cribed In the auditors, re$pon$ibilille8 for the 8udil of the financial stalgments sgdion of our r8Frt)rt. We are independent of the charitsbie cornpany in accordance with the ethical requirements that are relevant to our audit of the financial statemen15 in the UK. including the FRC'S Ethical Standard, and we have fuffillgd our other ethicol ro$wn$ibilitlo8 in accordance wth Ihese requirements. We believe that the audit evidence we have obtained is sufficlenl and appropriate lo provide a besis for our opinion. Conclu8lon8 r•l•tlng to golng conearn In auditing the financi818lalement8, we havo concluded that the tru8t888' U88 of the going C￿￿Orn basi8 of accounting in the preparation of the financial statemonts 18 8pproprfatè. Based on the work we have pèrfomed. we have not identif￿d any material uncertaint￿$ relating lo events or condrtions thal, individually or collects'vely, may cast svJnificanl doubt on the ¢haril8bla comp8ny'8 ability lo continue as a going ¢on¢orn for a pèriod of at least tsvelve month5 from when the financial 8talements are authori88d fof issue. Our responsibilities and thè r88pon8ibilitie8 of the tru818e8 Wth respect lo going ¢orK8rn are de8crfbed in the relevant sections of this report. Other infomatlon The other informallon compri88s the information included in the annual report, other than the lin8nci81 slalements gnd our audltors, report Ihereon. The Iru$tses are rèsponsib￿ for the other infofmation. Our opinion on the finoncial statemen18 does not cover the other infomation and, excèpt lo the extent oth8rwi8e explicrtly stal•d in our report, we do not express any form of assurance conclusion Ihereon. In connection with our audit of the financial statements, our re$pon8ibilty is to read the other information and. in doing so. consider whether the other information is malgrially incon¥i¥tenl with the financial 8tstemenls or our knowledge obtalned in the audit or otherwise appears to be materially misstated. If we identsfy such mo19ri81 inconsistenoies or 8pparenl m8terial mi88tstgments, we are required lo detemine whether there is a material misstatement in the financial 8tatemenl8 or a matsrial mi8$tstemenl of the other information. If, based on the work we have performed, we conclude that the￿ is a material misstslement of Ihls other information., we aro required lo report th8t fact. We have nothing lo report in Ihis regard. 19 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Independent Audltor3' Report to the trustees of HEART UK Opinion on oth•r matters prn6cribod by the Companl•s Act 2006 In our opinion, basèd on the work undertaken in the coursè of tha audit.. the infomialion given in thè trustees. annual report for the financial year for which the financial statements are prepared is consistent with the financial statements,. and the trustee8' annual report have been prepared in acc(Kdance with applicable legal requirements. Mattorn on whlch w• ar• raqulmd to r•port by •xc•ption In the light of the knovAedge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, wè have not idBnlified material mis6talements in th8 Iru51ees' annual ieport. We have nothing to report in r8sp8Ct of the following m8tter8 wher• the Companies Act 2006 and the Charitie8 Act 2011 require u8 to report to you rf, in our opinion.. th8 parent charitable company has not kept adequate and sufficient accounllng words, or Teturns adequate for our audit have not been received from branches not visited by us,. or the parent charitable ¢ompany's financial 8tatements are not in agreement with Ihe aC￿untIng record8 and tetums., or certain disclosures of Irusto85' romuneralion specrfiad by law arè not mad8; or we have not received 811 th8 Informaiion and explanations we require for our audit. the Iruslaes were not enlilled lo prepare the financial 8tstemen18 in 8c¢ordan¢¢ with the small compani08 regime and take 8dv8ntsge of the Small compan￿8 eXeMpt￿n in preparing the Tru8tees' Annual Report and from preparing 8 slrat¢9i¢ rep¢Yt. R••pon•ibllltlo8 of truste9• A¥ explained more fully in the statement of Iruslees, reBponsibilitlgS 8el out on page 17, the Iru81ee8 (who are a180 the dire¢lors of the charitable company for the purposès of comp8ny18wI are responsible for the preparation of the financial staleman18 and for being 8ali8fied ihal they give a tru6 and fair view. ond IOT Such internal control as the trustees determinè is nK8$$ary to enable the preparation of financial $tstemenl$ Ihal are free from materkgl mi88talemenl, whether due lo fraud or errol. In preparlng the fi'n8n¢i81 statements, the Iruslees are responsib￿ for as¥e3¥ing thg group and p8rent charitable company's ability lo Continue a8 a going concern, disck)sing, ag applieable, mattérs related lo going concern and Using the going concern basis of accounting unles8 the Iruslees eilher intend to liquidate the gioup or PaTanl charitable company or to cease operations, or have no realistic alternative but lo do 80. Auditor•' ro•pon•lbllltlH for the audlt ol th• fin•ncial •t•t8monts We have been appointed as auditor under the Companies A¢1 2006 ar￿ 88Ct*)n 151 of the Charitie8 Act 2011 and report in accordance with those Acts. Our obJ'eclNes are to obtsin reasonable assurance about whether the financial statements as a whole are fre& from Mater￿1 mi5slatemenl, whether due lo fraud or error, and lo issue an auditors, report that includes our opinion. Reasonable assurance is a hHJh level of assurance, but bs not a guarantèe that an audit conducted in accordance with ISAS IUKI will a￿VayS detect a material mi8ststement when il exists. Misstatements can arise from fraud or error and are considered material if, indNidually or in aggregate. they could reasonably be oxpe¢led lo influenGe the economic decisHJns of users taken on the b8818 of these financial ytatements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above. lo deteel material mis51alemenls in respect of irrggularities. incluijing fraud. The Qxlenl to which our procedures are capable of delecling irreguLqrities. in¢luding fiaud is detailed bebw. 20 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Independent Auditors. Report to the trusto08 of HEART UK Audltor•' r•spon8ibilitiM for the audit of the financial •t•tsment• {contlnu•dl Explanatlon a8 to what exlent tho audlt wa8 ¢on8ldered cap•bl• of detoctlng Irregularttlo8. Includlng fraud The oty'ective8 of our audrt in Tespecl of fraud. are,. to identrfy and as8e88 the risks of materk91 mi88tstement of the financial statements due lo fraud,. to obl8in Sufficient approprk91e audit eV￿enCe regarding the assessed risks of material misstatement duè to fraud, through designing and implementing 8ppropriat& respon8e8 to those assessed risks,. and lo respond appropriatety to instances of fraud or suspected fraud identrfi8d during the audit. However, the primary fesponsibility fof Ihg prevention and d&tsction of fraud rests with both management and those charged wilh govemance of the ¢harilabl¢ company. Our approach wa8 as follow6.. We obtainod an understsnding ol the legal and regLtlatory reqLtiremenl8 applicab￿ lo the charit8blg company and consid8r8d that the most signrficant arè Ithè Companies Act 2006. the Charilie8 Act 2011, the Charity SORP, and UK flnancial reporting standards 88188ued by the Financial Reporting Council We obtained an understsnding of how the charitsble company complle8 with thesa requlrements by discussions with management and th08e charged with govemancts, We as￿Sed th& ri$k of material mi88tatement of the financial 8tstemenl8. including the risk of malefial misstalernenl due lo fr8ud and how it M￿h1 occur, by holding di8GU88ion8 with m8nagèment 8nd Iho8e charged with g¢)vernance. We inquired of management and tho66 charged wlh govem8nce a8 to any kn¢)wn in$tsnc￿ of non- complianco or $u$pecled non-compli8nce wrth laws and regulations. Bg$ed on thi3 understanding, we de8igned spgcrfK appropriate audlt procedures to Identwy in81anc88 of non- compliance with18W8 and r8gulatKJns. This included making enquiries of management and those charged with governance and obtainino addrtional coThoborative evidence a¥ requirod. A8 part of an oudlt in accordance with ISA8 IUKI ￿ 8x•r¢is• prof&88ional judgement and maintain professional 8c8plicism throughout the 8udit. We also.. Identify and asse85 the risks of material misstatement of the financial stalement8, whether due to fraud or error, d88ign and perform audit procedures responsive to those risks, and obtain audlt evidence that 18 sufficient and 8ppropri8te to prov¢de a basis for our Opin￿1n. The risk of not detecting a material mi88talemenl resulting from fraud is higher than for ono ro$ulling from error. a8 frau¢J may involve collusion. forgery, intentional omi88ion8, mi8repre8entslions, or th8 override of Intémal ¢ontrol. Obtain an understsnding ol internal control relevant to the 8udit in order lo dgsign audit procedures that are appropriate in the ¢1￿￿m$￿nces. but not for the purpose8 of expre88ing an opinK*n on the effeclivene5s of the group and pargnt charitablè company's intemal control. Ev81uale the appropTialeness of accounting policle8 used and the rea8onablene83 of accounting estlmates arKI relaled disclosures made by the trustees. Conclude on tho appropriateness of the trustees, Use of the going concem ba818 of accounting and, bas¢d on the audrt evKlence obtained, whether a material uncertainty exi818 related lo events or conditions that may cast svJn¢ficanl doubt on the group and parent charitable company's ability lo continue as a going ¢onc&m. If we conclude that a material uncertainty exists, we are required lo draw 8ttention in our audilorfs report lo the related disc105ures in the financial statements 01, rf such disclosures are inadequate, to modTfy our c¢Jinion. Our conclUs￿n￿ are based on the audit evidencg obtained up to the date ol our audito15 rewrt. However. future events or conditions may cause the group or parent charitable company to cease to continue as a going concem. 21 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Independent Audltors. Report to the trustees of HEART UK Auditor%' responsibilit1•8 for th• audit of tho flnanclal stat•ments l¢ontlnuod Evaluat& the overall presentation, Structure and cont&nl of the financial stalemenls, including the disclc)sures, ond whether the financial statements represent the undertying Iransactsons and events in a manner that achieves fair presentatson. Obtsin sufficient appropnale audit evidence regarding the financlal infomatk)n of the entities or busin8ss activities within the group to express an opinion on the consolidated linanc￿l statements. Wa are responsible for the direth'on. 8upervisbon ond performance of tho group audit. We remain so18ty responsible for our audit We communicate wilh those chargo¢J with govemance r89arding. among other mattors, the Plann￿ scope and timing of the audit and signrficanl audlt finding5, including any 8lgnrficanl deficiencie8 in internal control that we identify durin9 our audit. UB¢ ol th￿ report This report is made solety to the charilabk company'8 membors, as a body, in accordance wth Chapter 3 of Part 16 of the Compani88 Act 2006 and, in Tespecl of the con301idated financial 8tatemenls, lo the charity's trustees, as body, in accordance with Ch8pler 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state lo the charitable company's members and trust￿3 those matters which we are required lo stsle lo them in an auditor's report and for no other purpos6. To Ihg fullest extent permitted by law, wg do not accept or assume rosponsibilily to any party other than the charitable company, the chantable company'8 members, as a b¢xly. and the charity'6 trustees, Os 8 body, for our auf1il work, for Ihl$ f•PQrt, or for the opinion we have lomied. Lukè Holt Isgnlor Statutory Audltorl for and on behalf of Moore Kingston Smith LLP 6th Floor, 9 Appold Sireel London EC2A 2AP Oate.. 1 August 2022 22 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Consolldatgd Statement of Financial Activiti￿ (incorporating income and èxpondltur• a¢￿unt) for the year ended 28 Fobruary 2022 Unrmtfldod fund• 2022 Reotrlctod Totsl funds lund• 2022 2022 Tot81 lunds 2021 Not• Incom• from. Donations, legaeiés and gr8nts Charrt8ble activitiès Trading incomg Other inGome Investment Income 210,981 239.054 421,818 5.192 1.886 234,981 239,054 421.816 5,192 1.886 217,090 186,867 348,6TI 1,837 Total Incom• 878.929 902,929 r54,465 Expondltur• on: Raising funds.. Fundraising Expenditur6 from trading Charrtable aclivitk88 102,381 356,377 102.381 359,919 74,570 229,475 562 278 4,542 Total •xp•ndlturo 1.012,160 4,542 1,016.692 866.323 N•t l•xp•ndltur•) I Incom• Nel gain on inve8tment8 1133,221) 6,286 19.458 {113,763) 5,286 (111,858) 4,354 15 Not movemont In fund• 1127,936) 19,468 {108,478) 1107,5041 R•conclll•tlon of fund•: Total funds brought forward Ti>tsl lund• carrl•d lorw•rd 676.112 075,112 682,616 447,176 19A58 466,634 575, 112 The notes on pageB 27 to 41 form part of these finanual 81atements. l amounts are derived from conllnuing activitie8. All gains and1068e8 recogn18ed in the year are included ab¢)ve. 23 Hyperlipidaemia Education & Atheroscler05is Research Trust UK (trading as HEART UK) (A company limited by guarantee) Gonsolldated Balanco Sheet a8 at 28 February 2022 2022 2021 Note Flxod as¥ets Intangible a88Ots Tangibl• as88t8 Investments 13 14 22,088 468 30,874 19,773 52,616 15 57,901 80,457 103,263 Currgnt a8••t• Debtor8 18 160,975 495,607 233,819 Cash at bank and in hand 393,357 666,682 627, 176 Crodltorn: amoun18 fal￿n9 due within one year 17 270,40S 155,327 N•t Gurrent Js••ts 388.177 471,849 Net aMot8 406,034 575, 112 Ch•rlty Fund• Re8trKted fund$ 18 19.458 447.176 Unrestrfcted fund8 18 575, 112 Total fund• 466,034 575, 112 A8 permitted by 8408 Companies Act 2008. the company has not presented Its own income and expendlture statement and related note8. The company'8 los$ for the year wa8 £108,47812021'. £107,5041- The charity's financlal gt8temenls have been prepared in accordance with the provi51ons applicable to companies Subject to the small companles regime. The financial Statements were approved and aulhorised for18gue by the trustees on..6/.7/. & a.. and signed on their behalf, by- nJJa Mr P Green, Chalrman qr N R l>hipp¥, Trust The notes on pages 27 10 41 fofm part of thgse financkg18lalemenls. Registered c¢%mpany number.. 02631049 24 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Charfty balance 8hoet a$ at 28 Fobruary 2022 2022 2021 Nots Flxod asget8 Intangible a88ets Tangible assets Inveslmonts 13 14 22.088 30.874 19.T73 15 57,903 52,618 80,459 103,265 Current ass•t8 Debtors 49,762 106,094 Cash al b8nk and in h8nd 362,995 386,455 412.757 492,549 Crndltorn.. amounts falling due within onc ycar 17 26.582 20, 702 Net current assets 386 175 471847 Net ass•ts 466,634 575, 112 Charlty Funds Reslricted fund8 18 Unrestricted funds 18 575, 112 Totsl fundj 466,634 575, 112 Th& charity's financial slal8m8nls have been prepared In accordance ￿th the provi81on5 appllcable to ¢ompanle$ subject lo the Small companies reglme. The financial stal8ments were approved and aulhorised for Issue by the trustees on.././j%. and slgned on their behalf, by-. Mr P Gr&&n, Chalnnan iiir N R F•hlpps, Trusteg The notes on pages 27 10 41 foim part of these financial statements. Registered company number.. 02631049 25 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Con801idated Ststement of Cash Flows for the ygar ended 28 February 2022 2022 2021 Not• Cash Ilow8 from operatlng a¢tlvitièB Nel cash lu$8d in)IprovKled by operatsng actwkies 20 104.844 (191,503) Cash ftow• from Inv•8tlng actly1t1￿. Purchase of intangible fixed as8elB Purchas8 of tangible fixed as8e18 Purchase of listèd inveslm8nl8 Dispo$81 of listed investments 13 14 15 15 {2,3941 12,683 N•t ¢a•h u•od In Invo•tlng actlvltlo• 12.394) 12,683 102,200 (178,820) Chang• In ca•h and cuh •qulval•nt• In th• y•ar Cash and ca8h equivalents brought forward Ca•h and ¢uh •qulval•nts ¢•rrl•d lopM*rd 393,357 572. 1 r7 21 495,607 393,357 Tho notes on ptyes 27 to 41 fom) part of those financlal statements. Analysls of consolldated net Mour¢e8 At28 February 2022 At 1 March 2021 Cash flow Cash at bank and in hand 393,357 102,250 495,607 26 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notss to the financlal statements 2for the year ended 28 February 2022 1. Accountlng poll¢le8 1.1 Ba818 of pr•poration of financlal statemonts The financial statements have been p￿pared under the historical cost convention as modffied by the revaluation of investments lo market value and in compliance with Accounting and Reporting by Charities: ststemenl of Recommended Practice applicable to chorities preparing their financial stotements in accordance with the Financial Reporting Stsndard 102 including Update Bulletin 2, "The Financial Rep)rting Standard applicable in the United Kingdom and the Republic of Ireland" I'FRS 102.1 and the Ch8rrties Act 2011. Ftyperlipidaemia Educ8tion & Alher08Cter0818 Research Trust UK (HEART UK) 1$ a company limited by guarantee and a registered charity and incorporated in England and Wales. HEAR T UK meets the definition of a PLbblic benerrt entity urKl¢r FRS 102. The financk81 statem8nts are prepared in sterting whth is the functional currency of th& Group, Monglary amounts in Ihese financial $lalements are rounded to the nearest pound. The Statement of finon¢ial aelivities ISOFAI and 8alance Sheet consolidate the financial stalernents of the ¢harty and ils subsidiary undertaking, The results of the subsidiary are consolidated on a line by lin8 basis ar￿ thé detailed rgsults ar6 di8c108ed in notg 24 of the financial statements. 1.2 Golng coTrc•rn The Iruslee5 have assessed whether the use of the going concern ba818 is appropriate 8nd have considered possible evenl8 or condition5 that might cast signifitsnt doubl on the ability of the company lo continuè a$ a going concern. The Iru$tee$ have made this assessment for a period of alloast one year from th8 dale of approval ol the financial slalements, In particular the Iruslees have considered the companys fofecasl8 and projections and have taken account of Ihg Coronavirus pandgmic. The company had adequate rèsources lo continue in oporalion for at lea81 ￿e1ve month8 from the approval of the financial 6tatemenl8. The company therefore ¢onlinue8 lo adopt the going concern ba818 in prepafing its financial stst¢ments, 1.3 Fund accountlng Genero1 funds are unrestricted fund8 wh￿h are available for use al the discretion of thè Iruslees in furtheiance of the general objective$ of the charity and whl¢h have not been designated for other purpos88. Restricted fund8 are funds which are lo b8 used in accordance specrfK restrictions imp08ed by donors or which have been raised by the charty for particular purposes. Th8 costs of raising and administering Such funds are charged against the specrfic lund. The aim and use of each restr¢tad fund 18 sel out in th8 notes to the financial 81alemenls. Those funds which are not reslricled income funds, afe unrestriclgd income funds which are sub analysed be￿88n designated fund5, where trustees have Sel aside amounts lo be used for specifK purpose8 or which reflect Ihg non-binding wishes of donor5', and unrestr￿ed funds, which are used at the Iru$tee8' discretion in furtherance of the general objectives of HEART UK. 27 Hyperlipidaemia Education & Atherosclerosis Research Trust UK {trading as HEART UK) (A company limited by guarantee) Notss to the financial $lalements for the year ended 28 February 2022 1. Accounting poli¢i•s {continu•dl 1A In¢omo All Incorne is lecognised once the charity has enlillement lo the income, it is probable Ihal the income wlll be reeeived and the amount of income receivable can be measurod reliably. For legacies, enlitlemenl is taken 88 the earlier of the dale on which etther.. the charity is aware Ih8t probate has been granted, the eBtale ha$ been finalised and notification has been made by the executorlsl to the Tru81 thal a distribution will bè made, or when a dkstribution is re￿￿0￿ from the estate. Receipt of a legacy, in whole or in part, 18 only consKlered probabk whgn the amount can be measured reli8bty and the charity has beèn notrfiod of the executor's inten￿n lo make a distribults)n. Whère legocies have been nolffied lo Ihg charity, or thg charity is 8war6 of the grantin9 of probate, and the criteria for income recognition have not been met, then the kgacy ¢8 Irealed a8 a contingent a5801 and disclosed if material. Donated Services or facilities are recognised when the charity has control over the item, any conditlon$ a880ciated with the donoted item have bgen mel, the receipt of economic benèfit from the use of thè charity of the item 18 probable and that economi¢ benefit can be measured reliably. Donated services are v81ued al the 8mounl HEART UK would be preparod lo pay for a skniiar service. Inter651 on funds held on deposit is included when receivable and the amount can be measured reliably by the ¢hority', this is norm8lly upon nolfficalion ol tho interest paid or payable by the bank. Income tsx recovefable in relation to don8lb)ns received under Grft Ald or degd8 of coven8nl is recogni88d al the lim¢ of the donation. Trading income reprgsenls lumover In the trading subsidiary which congrnts of conferoncg sponsorship8. d8189al& income, produGI licence fees and other serv￿9 and are accounted net of any discounts and exclusive of value added tax. 1.5 Ex￿ndItUr• Expenditure 16 recogni8ed once there is 8 legal or con8tru¢livo Obl￿at￿)n to transfer economic benefit to 8 Ihlrd party, il 18 probable that a transfer of 8Gonomic benefi18 will b& requireLI in 8elllemenl and the amount of the oblwJation can be mgasvred reliabty. Expenditure is classlfied by aclivrty. The C0818 of e8¢tt activity are made up of the total of direct Gosls and shared costs, including support costs invofv8d in undertaking each activity. Direct o$1¥ attributsble to a single activity are albcaled directly lo that athity. Shared costs which contribute to more than one activity and support C08ts which are not attributable to a Single activity are apportioned behveen those actwilies on a basi$ ¢on$islent wrth the use of rw)urce8. Central staff costs are allocated on thg basis of tsme Spent. and depreciation charges allocated on the Port￿ of the aso01'¥ us8. Costs of gengrating fund8 are costs incurred in attracllng voluntary income, and those incuried in trading actwilies that raise funds. Charitable xlivltios are costs incUr￿lj the charitV8 educational cpwalion8, including support costs apportioned to ¢haritsble activitie8. 1.6 Opgratlng l•a808 Leases that th not transfer all the risks arKI rewards of ownership are classlfied as op&r8ting leases. Payments undei operating leases are charged to the SOFA on a straight line basis over the period of the lease. Incentives re￿IVed to enter into operating leases are credrtod to the SOFA to reduce the tease 8xpen8e, on a $lraighl line basis over the p8r#)d of the lease. 28 Hyperlipidaemla Education & Athen)sclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notos to the financial 8tsternents for the year ended 28 February 2022 1. A¢¢ountln9 poll¢ie8 l¢ontlnuod) 1.7 Employoo banofits The charity operates a defined contribution pension 8nd death in service 8cheme. The pension charge repfesenls the amounts payable by the charity to the fund in respect of th6 year. 1.8 Intangibl• flx•d a¥sots and •mortl8atlon Intangible assets are c8pilalised and recognised when future economic benefit8 are probable and the c08t or value of the asset can b8 measured rgliably. Intangible assets are initialty recogni8ed at cost and are 8ubsequently moasured al cost net of amortisalion and any provision for impairment. IntsngibL9 assets 8re capitlbsed where the purchas& price exceeds £500. Amorti8ation is providad on intangible fixed assets al rates cakulated to Wfite off th8 CO8t of each a88et, 1888 their e81imatod ra8klual value, ovar their expected useful live¥ on tha following ba8e$.' Web8rt8 dev8lopmenl 20% straight line 1.9 Tanglbl• Ilx•d a8••t• and d•procl￿On Tangible fixed assets are carried al cost, n81 ol depreciatson and any provlsion for impaimenl. Doprea8tion is prowded 81 rates calcul8ted lo write off tho c081 of fixed assets, 1gS8 their estimated Te8idual valuè. over their expected u8oful Ilv88 on the following base8'. Tangible a88els are e4pllli8ed where the puTcha80 pr￿8 exceeds £250. Office equipment Computer equipment 15% 8lralghl line 33% slraighl line 1.10 Flxod au•t Invostm•nt• Fixed asset investmen18 are a form of financial instrument and Ofe inltialty recogni8ed at thoir transaction cost and subsoqu¢nlly measured at fair volue al the balance 5hget dale, unless fair value cannot bè me88ured reliably in wh￿h case it is measured al cost les8 impairn1gnt. Inve51m6nl gain8 and losses, whether Tealised or unrealised, are combined 8nd shown in the heading 'Net g$insl{1088e81 on inve8knents' in the Statement of financial aclivilie8. The investsnenl in subs￿19ry 1$ v81ue at cost. 1.11 0•btorn TTad8 and other dgbtors arg r¢cognised at the settlement amount after any trade discount offerod. 1.12 Ca•h at bank and In hand Cash al bank and in hand includes cash and short term highty liquid inveslments with a short m8turity cl three months or less from the dale of acquisttton or opening of the deposit OT similar a¢Gount. 29 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Note¥ to the financial statements for the ￿ar ended 28 February 2022 1. Accountlng pollcle# (continuadl 1.13 Financial In•trument8 The charity only has financial assets and financial liabilities of a kind that qualfy as basic financial in8trument8. Bas￿ frnancial instruments are initially recognised at Iransactyon value and subsequently measured al their settlement value witti the exception of bank loans which are sub80quenlly measured at amortised c081 using the effective inlei851 meth¢xl. 1.14 Crltlcal •¢countlng ludgemonts and o$tlmatlon unc•rLglnty Estim8ts8 and ju¢Jgments are continually evaluated and Ore based on histor￿81 exporierKo and other factors, including expectalions of future events that are bèloved to be reasonable under the Gircumstances. Slgnlllcanl accounting judgements and g$timale8 include.. Legacy accrued ineome Depreciation and amortisalion rateB CVD A¢¢rued income •. Useful oconomlc IIv•8 of tanglbl• and Intanglble a••et• The annual deprecialbon and amortisation charge for fix8d a$5ets is sen811ive to ch8ng&s in the estimated y￿fUl economic lives of the assols. The useful economie Iivg$ are re-assessed annually. Th98e are am8ndgd where necessary to reflect ¢urrenl eslimales, based on lachnological adv8nc8menl, future inveslmenls, o¢onomic utilisalion and the physical condition of the a58e18. See note8 13 and 14 for the carrying value of assets and note 1.7 and 1.8 for the useful econcffiic lives. 30 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to the financial stat•ments for the year ended 28 February 2022 Income from donations, legacles and grants Unrn8trl¢tod nds 2022 R•8tri¢t fund8 2022 Total funds Total funds 2022 2021 Donations 143.208 32.846 9,928 25.000 143,208 32,B45 9.928 49.000 234,981 170, 148 37,000 9.942 Legac￿8 Gift aid Grants 24,000 Totsl donations and legacie8 210,981 24.000 217,090 Total 2021 217,090 217,090 Charltable actlvltles UnroBtrlct•d lund• 2022 funds 2022 ToL•l funds Tol81 lunds 2022 2021 Fundraising 239.054 239.054 186,867 239,054 239,054 186,867 Tol812021 186,867 186.867 4 Tradlng Income Unmtrlct funds 2022 Restrlctod fund8 2022 Tot•1 fund$ Total ftinds 2022 2027 Income from trading subsidiary 421816 421816 348 671 Please see note 24 for details of th& trading subsidiary income. 31 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notès to the financial sLitements for the year ended 28 February 2022 Other Income Unrn8trlctod fund8 2022 Re6lrlctod fund• 2022 Total fund• Tot81 fvnds 2022 2027 Olhef income 6.192 6.192 Total 2021 Investment Income Unre•trlct•d lund• 2022 RMtrlcted fund• 2022 Tot•1 fund• Tot81 funds 2022 2021 Dividend received Intere81 recgived 187 1,650 1,888 1,686 1,886 1,886 1,837 Tol812021 t,837 1,837 7 Ralslng fund$ Unrn8trlctod fund8 2022 R•strl¢ted lund8 2Q22 Total fund• Tot81 funds 2022 2021 Staff c051s Other fundraising costs 69,738 32,643 69,738 32,643 46.334 28,236 Total 102,381 102,381 74,570 Total 2021 74,570 32 Hyperlipidaemia Educatlon & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) N¢)tes to thfr financial statsments for the year ondod 28 Febft￿ry 2022 Trading costs Unrn8trlct•d funds Restrfctsd funds 2022 Total fund8 Total funds 2022 2022 2021 Staff c08ts Direct costs Administrative expenses 49,804 287,180 48,593 49.604 261.722 48,693 59,378 129,477 40,620 4,542 Tol81 355,377 4,642 359,919 229,4T5 Charltable actlvltle8 Unr••trlctod fundi 2022 R08trlcted fund• Total fund• 2022 Tot81 funds 2021 2022 Awaren•8$, education and patient 8UPPOrt 527.162 527,162 537,297 Govemance c0818 Inole 10) 27,230 27,230 24,981 654,392 554.392 562.278 10 Governanca co8t8 Unrn8trlctsd fund8 2022 •trlct•d fund8 2022 Total fund• 2022 Total fund 2021 Audr( and accountancy fee$ 27,230 27,230 24,987 11 Net movement In funds Thr¥ is ststed after charging.. 2022 2021 Depreciation of tangible fixed assgts.. Amortisation of intangible fixed assets Auditor's remuneration - audit Audito¢$ remuneration- non audit servicgs 17,fA6 11.180 13,085 6,302 11,352 12,698 33 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to the flnanclal statements for the year ended 28 February 2022 12 Staff costs 2022 2021 Wagas and saLgrras Social sgcurity costs Other pension costs TefminalKJn costs 297,347 28.120 17.769 10,588 332,457 34,979 17,543 343,226 384,979 The avera98 nun¥)ar of employees during the year was 812021.. 9} The average number of fu1141me equivalent employees lincluding casual and part timo Stoffj during the year wa8 m8da up as folbws.. 2022 No. 2021 No. Charitable oper*ions Management and cenlr818ervices The number of èryloye8s whose remunefalion 8xceed £60,000. 1$ Shown bg10w.' 2022 No. 2021 No. £60,oc￿ to £69,999 Kay management personnel con8i8t8 of the leadership managem8nl team and con81818 of four12021.' 41 individuals. Total remuneration lo key management personnel totalled £218,982 in the y6ar12021'. £239,373). During the year lolal travel expense$ of £Nil {2021.' £nil were reimbursed to O {2021.. 01 Tru8tee8.l. During the year 4 Iruslees12021.. 01 donated a total of £15212021'.£nil), 13 Intanglble flxed assets W•b8lt• dovelopm8nt Group and Charlty C￿t Al 1 March 2021 Additions At 28 February 2022 Amortisation At 1 March 2021 Charge for the year Eliminated on disp0581s At 28 February 2022 Carrylng amount At 28 February 2022 55,499 2,394 67.893 24,625 11,180 35,805 22.088 Al 29 February 2021 30,874 Hyperllpldaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notes to the financial statemènts for the year ended 28 February 2022 14 Tanglblg fixed assets Offlce oquipmont Computer •quipm•nt Total Group and Charlty Cost At 1 March 2021 Disposals At 28 Febnjary 2022 33,753 9,5851 405 34,158 9.5851 24.168 405 24.573 D•prnclatlon Al 1 March 2021 Charge for the year Eliminated on disposal 14,143 17.483 17,9261 242 163 14,385 17.646 17.926} Al 28 February 2022 23,700 406 24.105 C•rrylDg amount Al 28 February 2022 Al 29 February 2021 19,610 163 19, 773 15 Flxed asset Inveslment8 Group 2022 Ch•rlty 2022 2021 2021 Investments at market valu6 Investment in 8ub8idiary at C051 57,901 52,816 57,901 52,616 57,901 52,616 57,903 52.618 2022 2021 M•rkot v•lu8 Al 1 March 2021 Additions Disposals Nel gainsll10ssosl Al 28 February 2022 52,616 60,945 112,883} 4,354 5.285 57.901 52,616 Historical cost of listed investments 50,000 35 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) {A company limited by guarantee) Notes to the financ•al statements for the year ended 28 February 2022 15 Flxèd assèt investments (continued) Slgnlllcant Inv•thent holdlng8 ba*•d on m•rket value al 28 February 2022 wern: Hlstorlcal Costs Mark value {£) 57,901 57,901 1£ COIF Char￿.85 Inve81menl Fund 50.000 50,000 16 Debtors Group Ch•rlty 2022 2021 2022 2021 Trade del)tor8 Amounts ¢)wed by group undertakings Other debtors Prepaymen18 and accruod income 95.625 55,100 12.526 22.084 10,500 18,508 10,429 168,819 86.360 37,237 85.694 Amount• duo ovor l year Prepayments and a¢¢rued income 9,900 9,900 124 602 17 Credltors: Amounts falllng due wlthln one year Group 2021 Ch*rfty 2021 2022 2022 Trade creditors knounts owed to group undertakings Other taxation ond social security Other credllors Accrual8 and def8rr8d income 81, 190 16,644 21, 138 70,511 8,946 1,854 41,2T9 143 728 11,703 3,124 228,150 270 405 8. 702 3,240 72,624 165, 756 4.737 3,124 25,161 Deferred income in the charity relato$1o income lo support foT futurg events and are induded in creditors al the period end. Oeferred income on a group basis includes spon801sh￿ and li¢en¢e income earned in the subsequent financial year. Group delorred incom Brought forward Amount •dded Amount r•l•a•od Carrfed foprfard Deferred income 2022 41,101 41.101 172,317 Defenpd income 2021 41,101 Hyperlipidaemia Educatlon & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notss to tho flnancial statements lor the year ended 28 February 2022 18 ststemènt of funds . Group Net galn• Balan¢9 at and 28 F•bruary traniforn 2022 B•lan¢• at 1 M•rch 2022 Incom• Expondl￿r0 G•nèral funds General funds- 811 fund$ 676,112 878.929 (1.012,1501 5,285 447,176 Tot81 unre8lriel8d fijnds 575,112 878,929 {1.012.1501 5,285 447,176 R•8trictsd fund• Reslncted funds - $11 fund8 24.000 {4,542} 19,458 Total of fund8 575,112 902.929 11,016,692) 6,286 466.634 . Charlty N•t g•ln• Balance at and 28 F•bruary tr•n8f•rn 2022 Bal•nc• •t 1 March 2021 In¢om• exp•ndlturo G•ner41 fund• Gener81 fund$- 011 funds Total unre8lrlcted fund8 675,112 675,112 519.010 519,010 1652.2311 1652,2311 5.286 5.285 447,176 447,176 R•8trlctsd fund8 Restricted funds - 811 fund8 To181 of furKI$ 24,000 {4,642} 666 773 19.468 575,112 37 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) IA company limited by guarantee) Note8 to the flnanclal Statements for Ihg year onded 28 February 2022 19 Analysls of nèt assets between funds Group Unrestrf¢ted funds 2022 Total funds Rostrict•d fund8 2022 2022 Intangible fixed 885el8 T8ngible fixed assets Fixed as¥gt investments Currgnl assets Cradrtors due within one year 22.088 22.088 67,901 637,124 1270AO61 447.176 57,901 656,582 {270.4051 486,834 19.4S8 19,458 Charlty UnrnBtrictod fund8 2022 R6•trlcted funds 2022 Total fundo 2022 Intangible flxed a8set8 Tangible lixed assels Fixed asset investments Current assets Creditors due wlhin one year 22,088 468 57.903 393.299 {26.5821 447,176 22,088 57,903 412,757 126,S821 466.634 19NSB 19,458.00 20 Reconclllatlon of net movement In funds to net cash flow from operatlng actlvltles Group 2021 2012 Net Ideficillllncomo for the year la8 per Statement of Financi81 A¢tivitie$) Adjustment for: Depreciation charge¥ Amortisalion charges Mel losses Profil on saK9 of r￿ed assets Increase in debtors increas& in creditors 1108.4781 (107,504) 17.646 11.180 {5,2851 1.659 72,844 115.078 6,302 11,352 (4,354) 1,178 (34,563) (63,914) (191,503) Net cash Iu8ed Inyprovlde by 0￿rating actlvftlfjs 104.644 38 Hyperlipidaemia Education & Ather05clerosis Research Trust UK {trading as HEART UK) (A company limited by guarantee) Notes to the financial 8tat•ments for the year ended 28 February 2022 21 Analysls of cash and cash equlvalents Group 2021 2022 Cash in hand 495,607 393,357 Total 495.607 393,357 22 Penslon commltment8 The group operates a defined contributions pension scheme. The pgnsion cost charge in the ytsr reF)r88ents contfibutions payable by the grtyjp and amounted to £17,75912021.. £17,543). 22 Operating lèasè commltmonts At 28 February 2022 the total futuro minimum laa8e payments under non-cancellable operating lea8es was: 2022 2021 Group and Charfty Within 1 year Belween 1 and 5 year8 Totsl 9,456 27,425 1,889 29,314 10.014 39 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Notos to the financial statements for the year ended 28 February 2022 23 Related party transactions Some of the trustees hold posit￿)nS wthin organisatKJns with wh￿h HEART UK has links. Some of those organisations may make donations lo, or seek product approval licenses frcm the charty or its trading subsidi8ry. Th8 charity has a conflict of interest policy in place lo ensure that potential conflicts are identified and dealt wrth appropriately. For the current and preceding yeor all tranSact￿nS with these reLgted parties are considered within the scope of nomi81 Iranwlions. An income distribut￿)n w88 made from HEART UK Tr8dlng Company Limited, a wholly owned subsidiary, lo HEART UK of £61,89Y12021-. £114.7941 being a distribution of 100% of their nel profil in the year. In addition, HEART UK Trading Company Limited was r￿harged salaries 01 £47,26912021.. £59,378) from HEART UK. Al the year 8nd an amount of £22,08612021'. £21,838) was owed by the subsidiary. 24 Prlnclpal subsldlary HEAR T UK has one wholw owned subsid￿ry, HEART UK Trading Company Limilad. whi¢h acts as Ihe trading Subsidiary of th¢ group and has been included in this 581 of consolidaled financial statements. The company has entered into a deed of covenant lo donate118 dislrlbulable profi18 lo HEART UK. The regisleftsd office of the subsidiary is 7 North Road, MaKlenhead, Befkshire, SL6 1 PE and 118 company number iy 03679100. A Summory of ils trading re8uII8 are 8h¢)wn below. A 8et of audited fina￿la1 stslemenl8 for this 8UbSKj￿ry are filed annually wth the Regislraf of Comp8n*8. HEART UK Tradlng Comp•ny Llmlt•d Mults 2022 2021 Proflt and lo•s Tumover Cost of Sal Admlnl•tr•tlvo Exp•n••• 421,818 1255.202) 1104,715} 344,268 (111,882) (t17, 590) Op•ratlng prollt 81,899 114, 796 Reconclliation of profll and los• ro••N Brought forward Operatlng profit 018trlbutlon to HEART UK 61.899 {61.899 114,796 (114, 796) Carrlod forward No charge lo laxats'on will arise as the 8ub8idi8ry company ha$ entered into a deed of covenant to don8te its distributable profi'ts to rts charitable parent HEART UK. 40 Hyperlipidaemia Education & Atherosclerosis Research Trust UK (trading as HEART UK) (A company limited by guarantee) Not•8 to th• flnanclal 8tstgmgnt8 for thg ygar ondèd 28 F•bNary 2022 24 Prfnclpal subsldlary (contlnued) Balanco Sh••L" 2022 2021 Curront ass•t• Doblors Cash al bank an¢J in hand 111.213 132,814 243,827 127.725 6,902 134.627 Cr•dltorn: amounts falling due within one year 243,8251 t16.117 N•t eurr•nl a•8•ts 18,510 C•pltal and r•80ry Called up ohare capital Totsl Equlty The Share captsl r6pre6ents 2 Ordinary 8hare8 of £1 each held by HEART UK. 25 Llmlted Ilabillty HEART UK is a ¢omp8ny limited by guaranteg and as su¢h does not havo share capital. In the evenl of winding up the liabilty of each member 18 limited to £1. 41